Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

613 results about "Arrestin" patented technology

Arrestins (abbreviated Arr) are a small family of proteins important for regulating signal transduction at G protein-coupled receptors. Arrestins were first discovered as a part of a conserved two-step mechanism for regulating the activity of G protein-coupled receptors (GPCRs) in the visual rhodopsin system by Hermann Kühn, Scott Hall, and Ursula Wilden and in the β-adrenergic system by Martin J. Lohse and co-workers.

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Spirocyclic dihydropyranopyrimidine KRAS inhibitors

Provided herein are compounds of Formula (IV-b), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein (e.g., a dysregulated KRas protein (e.g., a mutated or amplified KRas protein)). This disclosure also provides compositions containing the compounds as provided herein, or pharmaceutically acceptable salts thereof, as well as methods of using and making the same.
Owner:TREELINE BIOSCIENCES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Screening and application of novel plant heat-resistant gene

PendingCN119307506APromote productionGenetically modified cellsPlant peptidesTranscription RepressorGene
The application finds that the heat resistance of a mutant material ski2dcl4 generated by a large amount of 22nt siRNA is obviously enhanced, and the heat resistance is mainly mediated by 22nt siRNA generated at an SMXL4 / 5 site; after thermal domestication, 22nt siRNA generated at the SMXL4 / 5 site can inhibit the expression of SMXL4 / 5 protein, so that the inhibition on HSFA2 is relieved; the specific targeting transcription inhibition factor SMXL4 / 5 can be used as a novel plant heat resistance method to improve the tolerance of plants to high temperature stress.
Owner:SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

CAS9 proteins including ligand-dependent inteins

Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity of RNA-programmable endonucleases, such as Cas9, or for controlling the activity of proteins comprising a Cas9 variant fused to a functional effector domain, such as a nuclease, nickase, recombinase, deaminase, transcriptional activator, transcriptional repressor, or epigenetic modifying domain. For example, the inventive proteins provided comprise a ligand-dependent intein, the presence of which inhibits one or more activities of the protein (e.g., gRNA binding, enzymatic activity, target DNA binding). The binding of a ligand to the intein results in self-excision of the intein, restoring the activity of the protein.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Protein tyrosine phosphatase inhibitors and uses thereof

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatases, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions that respond favorably to PTPN1 or PTPN2 inhibitor treatment, such as cancer or metabolic diseases.
Owner:NERIO THERAPEUTICS INC

Antigen delivery platform and methods of use

Provided herein are compositions and methods for inducing an immune response in a subject, wherein the compositions comprise apoptotic cells, extracellular vesicles (EVs), and combinations thereof. Various compositions comprising mRNA encoding a microbial antigen are also provided. Further provided herein are compositions engineered to overexpress the human arrestin domain containing protein 1 [ARRDC1].
Owner:INTIMA BIOSCIENCE INC

Methods and compositions for treating epilepsy

Disclosed are methods and compositions relating to antisense therapy for treating epilepsy, such as a temporal lobe epilepsy, in a subject in need thereof by targeting Grik2 mRNA. In particular, the disclosure provides inhibitory RNA constructs capable of inhibiting expression of GluK2 protein and inhibiting epileptiform discharges in hyperexcitable neuronal circuits.
Owner:REGENXBIO INC +4

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Mutant of RSV (Respiratory Syndrome Virus) pre-fusion conformation F protein and application thereof

PendingCN119431524AInhibition transitionconformational stabilitySsRNA viruses negative-senseViral antigen ingredientsDisulfide bondingF protein
The invention relates to a mutant of an RSV pre-fusion conformation F protein, the mutant comprises amino acid mutation relative to an amino acid sequence of a wild type RSV F protein, the amino acid mutation is that amino acids at positions 392 and 493 or near the 493 are substituted by C, and a disulfide bond is formed between mutated positions 392C and 493C or near the 493C. The invention also provides a related DNA (deoxyribonucleic acid) coding sequence, a recombinant plasmid, an mRNA (messenger ribonucleic acid) sequence and a corresponding RSV vaccine. By introducing disulfide bonds at proper positions and combining with cavity filling, electrostatic mutation, proline mutation and the like, the expression and stability of the F protein with conformations before and after fusion and trimerization conformations are remarkably improved, and the F protein is remarkably inhibited from being converted into conformations after fusion. The mutant is also applied to preparation of RSV vaccines and detection of respiratory syncytial virus infection.
Owner:BEIJING NEOCURNA BIOTECHNOLOGY CORP +2

NF-kappa B inhibitor as well as preparation method and application thereof

The invention discloses an NF (nuclear factor)-kappa B inhibitor. The NF-kappa B inhibitor comprises N-trans-p-coumaroyl tyramine; the invention further discloses a preparation method of the NF-kappa B inhibitor. The invention also discloses an application of the NF-kappa B inhibitor in medicines for preventing or treating diseases related to body inflammation. According to the application disclosed by the invention, the influence of the N-trans-p-coumaroyl tyramine on a TLR4 / MyD88 / NF-kappa B inflammation signal channel is detected through an immunofluorescence technology, and a result shows that the N-trans-p-coumaroyl tyramine can be used for reducing the expression of TLR4 and MyD88 proteins and inhibiting the transfer of NF-kappa B proteins to cell nucleuses, so that the N-trans-p-coumaroyl tyramine can be used as an NF-kappa B inhibitor and can be used for preparing an anti-inflammatory drug. The composition is used for preventing or treating body inflammatory response.
Owner:GUANGDONG SECOND TRADITIONAL CHINESE MEDICINE HOSPITAL (GUANGDONG PROVINCE ENG TECH RES INST OF TCM)

Regulation of RAN translation by PKR and eIF2α-P pathways

Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure provides methods of inhibiting RAN protein translation by contacting a cell with an effective amount of an inhibitor of eIF2 phosphorylation or an inhibitor of protein kinase R (PKR). In some embodiments, methods described by the disclosure are useful for treating diseases associated with RAN protein translation, such as certain neurodegenerative diseases.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Survivin as a biomarker for predicting the responsiveness of cancer treatment

The present invention relates to a method of determining the responsiveness of a cancer patient to a treatment with a compound inhibiting KRAS protein or a mutant of a KRAS protein, or to a treatment with a compound inhibiting the interaction between MDM2 and p53, the method comprising measuring the level of Survivin in a first sample obtained from the patient prior to treatment with the compound, measuring the level of Survivin in a second sample obtained from said patient during or after treatment with the compound, comparing the level of Survivin in said second sample with the level of Survivin in said first sample, wherein the patient is determined to be responsive to the treatment with said compound when the level of Survivin in the second sample is decreased as compared to the level of Survivin in the first sample. The present invention further relates to the use of Survivin in a method for determining the ability of a compound to inhibit KRAS protein or a mutant of a KRAS protein, or of a compound inhibiting the interaction between MDM2 and p53, or of a pharmaceutical formulation comprising said compound inhibiting KRAS protein or a mutant of a KRAS protein or said compound inhibiting the interaction between MDM2 and p53, to treat cancer.
Owner:BOEHRINGER INGELHEIM INT GMBH

Anti-inflammatory active peptide as well as preparation method and application thereof

The invention belongs to the technical field of protein, and relates to an anti-inflammatory active peptide as well as a preparation method and application thereof. The amino acid sequence of the anti-inflammatory peptide is LLVK. The anti-inflammatory peptide fragment is spontaneously combined with I kappa B protein through hydrogen bonds and hydrophobic interaction to form a more stable compound, phosphorylation of the I kappa B protein is inhibited, secretion of inflammatory factors IL-1beta, IL-6 and TNF-alpha and a chemotactic factor MCP-1 is reduced, and therefore inflammatory reaction is prevented. The invention also provides a preparation method and application of the anti-inflammatory active peptide.
Owner:RUSHAN CITY HUALONG BIOLOGICAL TECH CO LTD

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Method for preparing pyridazinone compound and application of pyridazinone compound

The invention belongs to the technical field of pharmacy, and particularly relates to a method for preparing a pyridazinone compound and application of the pyridazinone compound, and the method comprises the following steps: step 1, reacting a compound as shown in a formula V with a Grignard reagent to obtain a compound as shown in a formula IV; 2, reacting the compound shown in the formula IV with succinic anhydride to obtain a compound shown in a formula III; 3, reacting the compound shown in the formula III with hydrazine hydrate to obtain a compound shown in a formula II; 4, oxidizing the compound shown in the formula II to obtain a pyridazinone compound; the pyridazinone compound or the pharmaceutically acceptable salt or prodrug of the pyridazinone compound can be used for inhibiting the activity of MET protein kinase and the mutant form of the MET protein kinase, and especially can be used as a Tepotinib intermediate.
Owner:SHENZHEN HUAXIAN PHARMA TECH CO LTD

Pharmaceutical composition for prevention or treatment of degenerative brain diseases comprising selexipag

The present invention relates to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, comprising selexipag or a pharmaceutically acceptable salt thereof as an active ingredient. Selexipag inhibits the expression and production of pro-inflammatory or inflammatory cytokines in brain tissue, inhibits the activity of microglia or astrocytes, inhibits NLRP3 inflammasome activity and CDK6 expression, reduces amyloid plaques, increases the expression of the amyloid beta-degrading enzyme IDE, and inhibits the hyperphosphorylation of tau protein and the expression of tau kinase, and thus can be effectively used as a novel therapeutic agent for the prevention or treatment of degenerative brain diseases, cognitive disorders, learning disabilities, or memory disorders.
Owner:DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Pharmaceutical application of sulfanyl acetamide compound

The invention discloses an application of a sulfanyl acetamide compound with a structure shown in a formula I in preparation of a medicine for preventing and / or treating tumors and idiopathic pulmonary fibrosis. The compound can be stably combined with key amino acid residues of DDR1 protein, has a remarkable inhibition effect on phosphorylation activation of the DDR1 protein and various tumor cells, plays an anti-tumor role by effectively inhibiting protein activity, and provides an effective lead compound for subsequent drug design. # imgabs0 #
Owner:NANJING DRUM TOWER HOSPITAL

Mutant of RSV pre-fusion conformational f protein and use thereof

Provided is a mutant of a respiratory syncytial virus (RSV) pre-fusion conformational F protein. The mutant comprises an amino acid mutation relative to the amino acid sequence of a wild-type RSV F protein, the amino acid mutation being amino acids at a position 392 and a position 493 or a position near the position 493 being substituted by C, and a disulfide bond being formed between a position 392C and a position 493C or a position near the position 493C after the mutation. Also provided are a related DNA coding sequence, recombinant plasmid and mRNA sequence and a corresponding RSV vaccine. By introducing a disulfide bond at a suitable position, and combining same with cavity filling, electrostatic mutation, proline mutation and the like, the expression and stability of an F protein having pre- and post-fusion conformations and a trimerized conformation are significantly improved, and the conformation of the F protein is significantly inhibited from being converted into the post-fusion conformation. The mutant is also applied to preparation of an RSV vaccine and RSV infection detection.
Owner:BEIJING NEOCURNA BIOTECHNOLOGY CORP +2

Application of amantadine in inhibiting ITGAV in preparing medicine for treating dry age-related macular degeneration

The invention discloses application of amantadine in inhibition of ITGAV in preparation of medicines for treating dry age-related macular degeneration, and belongs to the technical field of biological medicines. At present, no report for researching the ITGAV gene in the dry AMD exists, the specific action mechanism is not clear, and amantadine adaptation diseases do not include the dry AMD; according to the application disclosed by the invention, the gene target ITGAV is screened from mutual hair generation of microglial cells and RPE cells in a retina microenvironment, and amantadine is used for inhibiting ITGAV protein to relieve the progress of AMD, so that a new thought is provided for treating dry AMD. Experiments show that amantadine can inhibit ITGAV and delay EMT transformation of RPE cells. In a dry AMD mouse model induced by sodium iodate, RPE cell damage can be remarkably relieved by intraocular injection of amantadine, and the structure and function of a retina layer are improved. These results indicate that it may function in early intervention of dry AMD.
Owner:SHENZHEN AIER EYE HOSPITAL CO LTD

Composition and method for inhibiting expression of protein LPA(apo(a))

Provided in the present application are a composition and method useful for reducing the gene expression of LPA(Apo(a)) and for treating LPA-related diseases and conditions. Further provided are an LPA dsRNA agent, an LPA antisense polynucleotide agent, a composition comprising the LPA dsRNA agent and a composition comprising the LPA antisense polynucleotide agent, which are useful for reducing the expression of LPA in a cell and a subject.
Owner:SHANGHAI ARGO BIOPHARMACEUTICAL CO LTD

Modulators of BCL6 proteolysis and associated methods of use

Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation / inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
Owner:ARVINAS OPERATIONS INC